First Trust Advisors LP Has $5.89 Million Stake in HealthEquity, Inc. (HQY)
First Trust Advisors LP grew its position in HealthEquity, Inc. (NASDAQ:HQY) by 23.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 116,500 shares of the company’s stock after buying an additional 22,217 shares during the quarter. First Trust Advisors LP owned 0.19% of HealthEquity worth $5,893,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of HQY. Janus Henderson Group PLC increased its position in HealthEquity by 627.9% during the 2nd quarter. Janus Henderson Group PLC now owns 2,113,030 shares of the company’s stock worth $105,292,000 after purchasing an additional 1,822,732 shares in the last quarter. FMR LLC increased its position in HealthEquity by 45.6% during the 2nd quarter. FMR LLC now owns 2,235,150 shares of the company’s stock worth $111,378,000 after purchasing an additional 699,728 shares in the last quarter. TimesSquare Capital Management LLC acquired a new position in HealthEquity during the 2nd quarter worth approximately $25,822,000. BlackRock Inc. increased its position in HealthEquity by 4.3% during the 2nd quarter. BlackRock Inc. now owns 5,831,014 shares of the company’s stock worth $290,559,000 after purchasing an additional 241,061 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in HealthEquity by 6.2% during the 1st quarter. Vanguard Group Inc. now owns 4,115,237 shares of the company’s stock worth $174,691,000 after purchasing an additional 240,136 shares in the last quarter. Institutional investors own 91.75% of the company’s stock.
HealthEquity, Inc. (NASDAQ HQY) opened at $49.86 on Thursday. HealthEquity, Inc. has a 12-month low of $37.62 and a 12-month high of $55.31. The stock has a market cap of $3,010.52, a P/E ratio of 79.00, a price-to-earnings-growth ratio of 2.18 and a beta of 1.77.
HealthEquity (NASDAQ:HQY) last announced its quarterly earnings results on Tuesday, September 5th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.14 by $0.13. HealthEquity had a net margin of 20.27% and a return on equity of 13.93%. The firm had revenue of $56.90 million during the quarter, compared to analysts’ expectations of $55.66 million. During the same period in the prior year, the company posted $0.16 EPS. The company’s revenue was up 28.7% on a year-over-year basis. equities research analysts forecast that HealthEquity, Inc. will post 0.7 EPS for the current year.
In other news, Director Frank Medici sold 419,504 shares of the company’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $52.97, for a total value of $22,221,126.88. Following the sale, the director now directly owns 6,381 shares of the company’s stock, valued at approximately $338,001.57. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Berkley Capital, Llc sold 373,500 shares of the company’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $53.21, for a total transaction of $19,873,935.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,563,591 shares of company stock worth $81,519,756. Insiders own 29.00% of the company’s stock.
HQY has been the subject of a number of research analyst reports. TheStreet upgraded shares of HealthEquity from a “c” rating to a “b” rating in a research report on Monday, July 31st. Cantor Fitzgerald reiterated a “buy” rating and set a $56.00 price objective on shares of HealthEquity in a research report on Monday, September 25th. Zacks Investment Research upgraded shares of HealthEquity from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research report on Wednesday, October 11th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $61.00 price objective on shares of HealthEquity in a research report on Wednesday, September 6th. Finally, BidaskClub cut shares of HealthEquity from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $57.50.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/11/16/first-trust-advisors-lp-has-5-89-million-stake-in-healthequity-inc-hqy.html.
HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.
Receive News & Ratings for HealthEquity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.